Bohuslav Melichar

机构：University Hospital Olomouc, Palacký University Olomouc · ORCID：0000-0002-5474-6866

发表论文 804 篇 · 总被引 47064 次 · h-index 75

代表论文

• Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial (2025 · Nature Medicine · 被引 55)
• Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study (2025 · European Urology Oncology · 被引 16)
• Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 12)
• Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study (2025 · European Journal of Cancer · 被引 10)
• Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study (2025 · Cancer Immunology Immunotherapy · 被引 10)
• VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer (2026 · Journal of Clinical Oncology · 被引 9)